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A b s t r A c t
It has been well recognized that the presence of left ventricular hypertrophy (LVH) 
is an adverse feature in hypertension, with such patients having a substantially higher 
risk of cardiovascular events, including mortality and morbidity from heart failure, 
ventricular arrhythmias, death from myocardial infarction, sudden cardiac death and 
cerebrovascular episodes.  ECG may show findings suggestive of hypertrophy but 
echocardiography is the preferred test for the evaluation of the presence and extent 
of hypertrophy. The reduction of blood pressure via life style interventions and with 
the use of antihypertensive agents reduces cardiac mass in patients with LVH. This 
reduction is related both to the degree of antihypertensive response and to the spe-
cific therapy used. It appears that the degree of regression is more pronounced with 
angiotensin-converting enzyme inhibitors and calcium channel blockers, especially 
non-dihydropyridines. The regression of LVH is accompanied by a reduction in sud-
den death, acute myocardial infarction and heart failure.
I N c I D E N c E  A N D  D E f I N I t I O N  O f  H Y P E r t E N s I v E  
L E f t  v E N t r I c U L A r  H Y P E r t r O P H Y  ( L v H )
Left ventricular hypertrophy (LVH) is a common finding in patients with borderline 
or overt arterial hypertension and it can be diagnosed based on electrocardiographic 
(ECG) or echocardiographic criteria [1,2]. Even though the ECG may show findings 
suggestive of LVH, it is much less sensitive and therefore echocardiography is the 
preferred test for the evaluation of the presence and extent of hypertrophy. Echocar-
diography, usually with the M-mode technique, is the gold standard test, given the 
low sensitivity of the ECG criteria for LVH (only 7% to 35% in moderate hypertrophy 
and 10% to 50% in severe hypertrophy) [3]. 
LVH is defined as an increase in left ventricular (LV) mass due to myocardial wall 
thickening or LV cavity dilatation or both. This increase in LV mass is the result of 
the continued exposure to an increased afterload in arterial hypertension. The patho-
genetic mechanism involves an increase in the number and/or size of the individual 
sarcomeres in each cardiac myocyte. The normal LV mass in men is 135 g and the mass 
index is 71 g/m2; in women, the values are  g and 62 g/m2, respectively. Hypertrophy 
is defined as two standard deviations above the normal limits [4,5]. Data from the 
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Framingham Heart Study have shown that normalization of 
the LV mass index to height may be more accurate, the nor-
mal values being 163 gr/m for men and 121 gr/m for women 
[6]. Nevertheless, in clinical practice the presence of LVH is 
determined from the M-mode values or 2D measurements in 
the parasternal view. 
In addition to the increase in the absolute value of LV 
mass, the geometrical shape of the LV cavity is also important 
[7]. Patients without an increase in absolute mass, but with an 
increase in relative wall thickness or in the wall thickness-to-
cavity diameter ratio (called concentric remodeling) have the 
same adverse risk as those with an increase in both mass and 
relative wall thickness (called concentric hypertrophy).  In 
each case there is an increased risk not only for cardiovascular 
sequelae, but also for death, which is independent of the blood 
pressure level [8]. 
E t I O L O G Y
The development of LVH is a relatively premature re-
sponse to arterial hypertension, as is echocardiographically 
shown in children and adults with borderline hypertension 
[17]. Patients that develop transient but substantial increase in 
blood pressure values during mental or physical work may also 
tend to develop hypertrophy [18]. Ambulatory blood pressure 
(BP) monitoring has suggested the existence of two additional 
risk factors for the development of hypertrophy: the daily 
hypertensive load defined as the percentage of values above 
140/0 mmHg in the daytime and above 120/80 mmHg in the 
night time, and nocturnal hypertension, where the expected 
fall in blood pressure during the night rest is not observed. 
Other studies have suggested that the peak morning BP 
value, or the peak exercise value are more predictive of the 
development of LVH [1]. This may explain why ambulatory 
BP monitoring values are more closely related to the develop-
ment of LVH than the usual office BP measurement. 
There is also evidence showing an increase in LV mass 
before the development of overt hypertension [20]. Data from 
the Framingham Heart Study for example showed a direct and 
continuous relationship between LV mass and the subsequent 
development of hypertension in previously normotensive 
subjects [20]. The above observations may be explained by 
three mechanisms: the patients had higher mean BP values 
from the beginning; the same factors such as angiotensin 
II, epinephrine, norepinephrine, endothelin and increased 
sympathetic tone, in the heart and peripheral vessels, predis-
pose to hypertension and hypertrophy alike, and finally, the 
tendency to hypertrophy may be a genetic trait predisposing 
to hypertension as well.  
c L I N I c A L  I m P O r t A N c E
As regards the clinical importance of LVH, it is accompa-
nied by an increase in heart failure, ventricular arrhythmias, 
death from myocardial infarction, reduced ejection fraction, 
sudden cardiac death (SCD) and cerebrovascular episodes 
[13-16]. In a prospective study, 1033 hypertensive patients, 
free of cardiovascular incidents, were followed up for a median 
of three years [14]. The percentage of major cardiovascular 
events (fatal or non-fatal myocardial infarctions, SCD, se-
vere heart failure or severe renal failure requiring dialysis) 
was significantly higher in the 2% of patients who had an 
increased LV mass. After adjustment for other risk factors, 
LVH was associated with an increase in cardiovascular events, 
showing a relative risk of 2.08. For each increase in LV mass 
by 3 gr/m2 there was an increased risk for cardiovascular 
events of 40%.
A report from the Framingham Heart Study examined the 
relation of LV mass and hypertrophy with SCD in 3661 subjects 
over 40 years of age, who were followed-up for 14 years [17]. 
The incidence of LVH was 22% and the relative risk for SCD 
was 2.16 (p=0.008). For every 50 gr/m increase of LV mass 
the relative risk increased by 1.45 (p=0.008). 
LVH is also related to an increased risk of cerebrovascular 
events, both stroke and transient ischemic attacks, may be 
because it is a marker of more severe or prolonged hyperten-
sion. This was shown in a study of 2363 hypertensive subjects 
without previous cardiovascular disease, who were followed-up 
for 14 years [15]. The presence of LVH either in the ECG (18% 
of the study population) or echocardiographically (24% of the 
subjects) increased the risk of cerebrovascular events, with a 
relative risk of 1.7 and 1.64 respectively. For every increase 
in LV mass by one standard deviation on echocardiography, 
the relative risk of an event was 1.31. 
The increased cardiovascular risk of LVH may be in part 
due to myocardial ischemia that can be the result of several 
factors. The hypertrophied myocardium is characterized by a 
reduced density of capillaries. Moreover, the enlarged LV mass 
limits the coronary arterioles’ ability to dilate in response to 
reduced perfusion or during vasodilation [18]. The endocar-
dial capillaries may also be directly compressed. The above 
may result in reduced coronary flow reserve and have several 
clinical implications. 
In case of coronary artery occlusion the presence of LVH 
results in bigger infarcts and higher mortality rates, compared 
to the absence of LVH [1]. The hypertrophied myocardium is 
more vulnerable to the ischemic insult. In a study of patients 
that had suffered SCD the patients with hypertension and 
LVH had less extensive coronary artery disease and were less 
likely to have thrombi in the coronary vessels, compared to 
the normotensive ones [20]. 
The development of heart failure in patients with LVH is 
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the result of reduced systolic and/or diastolic function of the 
left ventricle. The adverse impact of LV remodeling may be 
a crucial factor promoting the progression of heart failure 
[21]. 
LVH also causes electrophysiological changes and a type 
of electrical remodeling, including changes in the action 
potential altered repolarization and dispersion of recovery, 
and easily provocable early afterdepolarizations. The latter 
are associated with an increased susceptibility to ventricular 
arrhythmias, especially torsade de pointes and SCD [22].
Patients with ECG evidence of LVH have a higher inci-
dence and greater complexity of ventricular premature beats 
and more serious arrhythmias than patients without LVH or 
normotensives [23-27]. This correlation is irrespective of the 
etiology of LVH. Ventricular arrhythmias are also increased in 
patients with LVH compared to normotensives or hypertensive 
patients without LVH [26,28-31]. In a study of patients over 
70 years of age, the presence of LVH, even in the absence of 
a history of hypertension, resulted in an increased incidence 
of ventricular arrhythmias [32]. 
The frequency and complexity of ventricular premature 
beats (VPBs) is related to the severity of LVH [28,2]. For 
example, a study of 4 patients without coronary artery dis-
ease, showed that the frequency and complexity of ventricular 
arrhythmias was closely related to the presence of LVH, as 
defined by the thickness of interventricular septum or pos-
terior LV wall more than 1.2 cm or the LV mass. For each 
mm increase in wall thickness there was a two- to three- fold 
increase in the occurrence and complexity of VPBs. In addi-
tion to the occurrence of spontaneous ventricular arrhythmias, 
LVH also results in an increased ability to induce sustained 
ventricular tachycardia (VT) in animals and humans [33,34], 
especially in the presence of coronary artery disease [35]. 
Little is known about the pathophysiologic mechanisms 
responsible for ventricular arrhythmias in the hypertrophied 
LV. Many theories have been proposed, but it seams that the 
genesis of arrhythmias in the hypertrophied LV is multifac-
torial, the main factors being ischemia, electrophysiologic 
disturbances, myocardial cell abnormalities, increased sym-
pathetic activity, fluctuations in blood pressure levels and 
electrolyte abnormalities from diuretic therapy in patients 
with hypertension. 
The fact that ventricular arrhythmias and SCD are fre-
quent in patients with LVH [36], does not prove that these 
arrhythmias precede ventricular fibrillation (VF) or fatal 
electrical events. It seems logical but remains unproven that, 
in a population documented to be at increased risk of SCD, 
such as patients with LVH, those with the greatest degree 
of electric instability are likely to be at highest risk. It is still 
unanswered whether the presence of ventricular arrhythmias 
in patients with LVH is a prognostic factor of SCD although 
several studies have shown that it is true for the complex ven-
tricular arrhythmias [37-3]. For example in the Framingham 
Heart Study 671 patients with echocardiographically proven 
LVH were studied. At the end of the 6 year period of follow-up, 
the all cause mortality was increased in those with complex or 
frequent ventricular arrhythmias compared to those without 
(38% versus 12% for men and 22% versus 11% for women) 
[35]. However, the increased mortality was only marginally 
significant after adjusting for clinical factors. In another study 
554 elderly patients were followed up for an average period of 
27 months [38]. Hypertensive patients with coronary artery dis-
ease and non-sustained VT on ambulatory Holter monitoring 
who had echocardiographically proven LVH were significantly 
more likely to experience VF or SCD, compared to those who 
did not have VT or who had VT without LVH (57% versus 
20% and 20% respectively, p<0.001). According to these data, 
it would seem logical that the regression of LVH would result 
in a reduction of ventricular ectopy and SCD. 
t H E r A P E U t I c  I N t E r v E N t I O N s
In general, the reduction of blood pressure via life style 
interventions and with the use of antihypertensive agents 
reduces cardiac mass in patients with LVH [33-35,3]. This 
reduction is related both to the degree of antihypertensive 
response and to the specific therapy used [41]. It appears 
that the degree of regression is more pronounced with ACE 
inhibitors and calcium channel blockers, especially nondihy-
dropyridines while it may not occur with direct vasodilators 
such as hydralazine and minoxidil [41,42]. 
The regression of LVH is accompanied by a reduction in 
ventricular arrhythmias. In animal models, the regression of 
LVH normalized the action potentials and suppressed the 
diversity of refractoriness, thereby decreasing the suscepti-
bility to the induction of polymorphic VT and VF [34]. A 
series of observations in humans shows similar results for 
some antihypertensive agents. In one study, the regression of 
LVH, after three months of treatment with a calcium chan-
nel blocker, decreased ventricular arrhythmia and this was 
associated with a reduction in LV mass [43]. In contrast, the 
patients treated with a diuretic had no reduction in either the 
LV mass or ventricular ectopy. Another study randomized 
46 hypertensive patients to enalapril, hydrochlorothiazide, 
atenolol or verapamil. All agents reduced blood pressure levels 
effectively. At six months, the LV mass index and ventricular 
ectopy were reduced in the subgroups of enalapril, atenolol, 
and verapamil. In contrast hydrochlorothiazide affected 
neither LV mass nor the impact of arrhythmias [44]. In an-
other small study, hypertensive patients were randomized to 
captopril or placebo [45]. Captopril therapy was accompanied 
by a reduction of LVH and ventricular arrhythmias. Another 
study using cisapril and isradipine showed similar results [46]. 
Based on these data it seems safe to assume that the reduction 
in ventricular arrhythmias related to the regression of LVH is 
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not due to a direct antiarrhythmic action of antihypertensive 
agents but rather due to their actions at the hemodynamic and 
possibly neurohormonal level. 
Not many studies exist for the impact of the regression of 
LVH on cardiovascular morbidity and mortality. In general, 
they support but do not prove a benefit beyond blood pres-
sure reduction [47,48,51]. Reports from the Framingham 
Heart Study have shown that the regression of LVH, based 
on ECG criteria, is accompanied by a reduction in SCD, 
acute myocardial infarction and heart failure [4,51]. Among 
patients with LVH the likelihood of a cardiovascular event 
such as, cardiac death, myocardial infarction, stroke, angina 
or need for revascularization, over a 10-year period was sig-
nificantly lower in those subjects that achieved LVH regression 
compared to those in whom LVH persisted (3% versus 25%, 
p<0.01). Moreover, patients with normal LV mass who did 
not develop LVH in the 10-year period had significantly less 
cardiac events compared to those who developed LVH (5.1% 
versus 31.6%, p<0.01). Similar benefits come from the LIFE 
trial, which compared atenolol with losartan [50]. Although a 
similar blood pressure reduction was achieved with both drugs, 
the regression of LVH was greater with losartan, especially 
in diabetics.  A further analysis of the trial data found that 
the incidence of SCD was significantly lower in the diabetics 
group treated with losartan compared to the patients treated 
with atenolol. 
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